About Telehealth NAD+.

What this site is

Telehealth NAD+ is a plain readout of the peer-reviewed research on NAD+ (nicotinamide adenine dinucleotide) and its precursors — a precise account of what specific studies measured, and nothing more. Read the record here, and one discipline runs above all others: the coenzyme NAD+ is kept distinct from its precursors NMN and NR, and a trial of an oral precursor is never described as 'taking NAD+.' Where the evidence is strong — that precursors raise blood NAD+ — the readout says so; where it is weak — hard clinical outcomes, IV efficacy — it says that too, in the same plain register.

A readout reports; it does not dose. Nothing here is diagnosed, prescribed, or treated, and no visit is on offer. It keeps no clinical staff and stocks nothing — no supplements, no infusions, no injections — so there is nothing to buy, source, or be prescribed. What it publishes is a reading of published science, every number tied to its study.

About the word "telehealth" in our name

The 'telehealth' in the name is framing, not a service. No telehealth visits, consultations, prescriptions, or pathways to obtain a product exist here. NAD+ is not an FDA-approved drug, and no legitimate 'prescription NAD+' telehealth pathway is implied. The name marks the position this readout occupies relative to the literature — a remote, plain-language account of the science — not a claim that anyone is connected to care or commerce. For a reader hoping to buy or be prescribed something, this is the wrong place: there is nothing here to purchase.

How we handle sources

Every quantitative claim — every dose, percentage, duration, and effect size — maps to a numbered citation in the cited references, drawn from PubMed-indexed journals including Science, Cell Metabolism, GeroScience, Scientific Reports, Nature Reviews Molecular Cell Biology, and Nature Metabolism. Findings are summarized, not extrapolated beyond. Regulatory statements — that NAD+ is sold as a supplement, that NMN's supplement status is contested by the FDA, that a compounded injectable NAD+ product drew a Class I recall — are reported as public record, not as endorsements or warnings about any specific product. No commercial supplement brand is named as a recommendation; where a brand appears, it is inside a journal citation's own title, reproduced verbatim, and nothing more. When the evidence is uncertain, it is left uncertain rather than rounded up into a claim.